Novel endomorphin-1 analogs with C-terminal oligoarginine-conjugation display systemic antinociceptive activity with less gastrointestinal side effects.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Biochimie

• Publication date

  2015-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.biochi.2015.06.008PMID 26115815
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diabetes attenuates the inhibitory effects of endomorphin-2, but not endomorphin-1 on gastrointestinal transit in mice.

  2014cited by this paper
• Characterization of opioid activities of endomorphin analogs with C-terminal amide to hydrazide conversion.

  2013cited by this paper
• Novel glycosylated endomorphin-2 analog produces potent centrally-mediated antinociception in mice after peripheral administration.

  2013cited by this paper
• Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain

  2013cited by this paper
• In vivo characterization of intestinal effects of endomorphin-1 and endomorphin-2 in type 1 diabetic mice.

  2013cited by this paper
• Endomorphin derivatives with improved pharmacological properties.

  2013cited by this paper
• Peripherally acting novel lipo-endomorphin-1 peptides in neuropathic pain without producing constipation.

  2013cited by this paper
• Bioavailability of endomorphins and the blood-brain barrier--a review.

  2013cited by this paper
• A new class of highly potent and selective endomorphin-1 analogues containing α-methylene-β-aminopropanoic acids (map).

  2012cited by this paper
• Peptide therapeutics for CNS indications.

  2012cited by this paper
• Synthesis and biological evaluation of an orally active glycosylated endomorphin-1.

  2012cited by this paper
• Lipo-Endomorphin-1 Derivatives with Systemic Activity against Neuropathic Pain without Producing Constipation

  2012influential reference
• Synthesis and antinociceptive effects of endomorphin-1 analogs with C-terminal linked by oligoarginine.

  2011cited by this paper
• Recent Advances in Endomorphin Engineering

  2010cited by this paper
• Opioid receptor targeting ligands for pain management: a review and update

  2010cited by this paper
• Characteristics of compounds that cross the blood-brain barrier

  2009cited by this paper
• Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides.

  2008cited by this paper
• Opioid complications and side effects.

  2008cited by this paper
• Enzymatic degradation of endomorphins.

  2008cited by this paper
• Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden

  2007cited by this paper
• Antidepressant-Like Effect of Endomorphin-1 and Endomorphin-2 in Mice

  2007cited by this paper
• Utilization of Combined Chemical Modifications to Enhance the Blood-Brain Barrier Permeability and Pharmacological Activity of Endomorphin-1

  2006cited by this paper
• Enzymatic degradation studies of endomorphin-2 and its analogs containing N-methylated amino acids.

  2006cited by this paper
• Synthesis and biological activity of N-methylated analogs of endomorphin-2.

  2005cited by this paper
• Crossing the blood-brain barrier: A potential application of myristoylated polyarginine for in vivo neuroimaging

  2005cited by this paper
• In vitro and in vivo opioid activity of [DPro(6)]dermorphin, a new dermorphin analogue.

  2003cited by this paper
• Antinociception by a peripherally administered novel endomorphin-1 analogue containing beta-proline.

  2003cited by this paper
• In vitro quantitative study of the degradation of endomorphins.

  2002cited by this paper
• Effect of guanidino modification and proline substitution on the in vitro stability and blood-brain barrier permeability of endomorphin II.

  2002cited by this paper
• Dissociation of analgesic and rewarding effects of endomorphin-1 in rats.

  2000cited by this paper
• Inhibitory effect of intracerebroventricularly-administered [D-Arg(2), beta-Ala(4)]-dermorphin (1-4) on gastrointestinal transit.

  2000cited by this paper
• Analgesic effects of endomorphin-1 and endomorphin-2 in the formalin test in mice.

  2000cited by this paper
• Brain drug delivery technologies: novel approaches for transporting therapeutics.

  2000cited by this paper
• Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine.

  2000cited by this paper
• Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse.

  2000cited by this paper
• Pain Inhibition by Endomorphins

  1999cited by this paper
• Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain.

  1998cited by this paper
• Central actions of endomorphins: new endogenous opioids.

  1998cited by this paper
• Transport of opioid peptides into the central nervous system.

  1998cited by this paper
• Proline specific peptidases.

  1997cited by this paper
• Spinal analgesic actions of the new endogenous opioid peptides endomorphin‐1 and ‐2

  1997cited by this paper
• A potent and selective endogenous agonist for the mu-opiate receptor.

  1997cited by this paper
• A novel chemical approach to drug delivery: lipidic amino acid conjugates.

  1994cited by this paper
• A specific enzyme assay for aminopeptidase M in rat brain.

  1992cited by this paper
• Pharmacologic evaluation of a cyclic somatostatin analog with antagonist activity at mu opioid receptors in vitro.

  1987cited by this paper
• Colonic bead expulsion time in normal and mu-opioid receptor deficient (CXBK) mice following central (ICV) administration of mu- and delta-opioid agonists.

  1987cited by this paper
• Colonic bead expulsion time in normal and μ-opioid receptor deficient (CXBK) mice following central (ICV) administration of μ- and δ-opioid agonists

  1987cited by this paper
• Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability.

  1985cited by this paper
• Segmental colonic transit time

  1981cited by this paper
• Sites of organic acid production and patterns of digesta movement in the gastrointestinal tract of dogs.

  1979cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976influential reference
• Sites of organic acid production and pattern of digesta movement in the gastrointestinal tract of swine.

  1975cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper
• Characteristics

  1895cited by this paper

• Peptide-derived ligands for the discovery of safer opioid analgesics.

  2024cites this paper
• BNT12, a novel hybrid peptide of opioid and neurotensin pharmacophores, produces potent central antinociception with limited side effects.

  2024cites this paper
• Novel endomorphin analogues CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favourable side effect profile at the spinal level

  2023cites this paper
• Novel Cyclic Endomorphin Analogues with Multiple Modifications and Oligoarginine Vector Exhibit Potent Antinociception with Reduced Opioid-like Side Effects.

  2021cites this paper
• Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.

  2020cites this paper
• The spinal anti-allodynic effects of endomorphin analogs with C-terminal hydrazide modification in neuropathic pain model.

  2020cites this paper
• Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action

  2020cites this paper
• A new tridecapeptide with an octaarginine vector has analgesic therapeutic potential and prevents morphine‐induced tolerance

  2018cites this paper
• Endomorphin‐1 analogs with oligoarginine‐conjugation at C‐terminus produce potent antinociception with reduced opioid tolerance in paw withdrawal test

  2018influential citation
• Endogenous Opiates and Behavior: 2015.

  2017cites this paper
• Endomorphins: Promising Endogenous Opioid Peptides for the Development of Novel Analgesics

  2017cites this paper
• Endomorphin‐2 analogs with C‐terminal esterification produce potent systemic antinociception with reduced tolerance and gastrointestinal side effects

  2017influential citation
• Noninfectious Fever in the Near-Term Pregnant Rat Induces Fetal Brain Inflammation: A Model for the Consequences of Epidural-Associated Maternal Fever

  2017cites this paper
• Antiallodynic Effects of Endomorphin-1 and Endomorphin-2 in the Spared Nerve Injury Model of Neuropathic Pain in Mice

  2017cites this paper
• Expression and physiology of opioid receptors in the gastrointestinal tract

  2016cites this paper